文献速递生殖医学

外显子组测序揭示严重精子活力障碍的已知与新型候选基因变异

Exome sequencing reveals variants in known and novel candidate genes for severe sperm motility disorders.
PubMed 文献 · Hum Reprod · 2021-01-01

该研究对21例严重精子活力障碍患者进行外显子组测序,在10例(48%)中检出已知基因的致病性变异,在7例(33%)中检出新型候选基因变异,支持外显子组测序作为该病的有效诊断方法。

要点

  • 外显子组测序在48%的严重精子活力障碍患者中检出已知基因致病性变异。
  • 在33%的患者中检出新型候选基因变异,涉及DNAH12、DRC1、MDC1、PACRG、SSPL2C和TPTE2。
  • 外显子组测序是诊断严重精子活力障碍的有效方法,诊断率为48%。

核心结论

  • 外显子组测序可诊断约半数严重精子活力障碍患者,并揭示多个新型候选基因。

研究设计与样本

  • 研究对来自阿根廷(n=9)和澳大利亚(n=12)两个诊所的21例严重精子活力障碍患者(活力<5%,正常形态0-4%)进行外显子组测序。

主要发现

  • 在10/21例(48%)患者中检出已知基因的致病性变异:CFAP43(3例)、CFAP44(2例)、CFAP58(1例)、QRICH2(2例)、DNAH1(1例)、DNAH6(1例)。
  • 阿根廷队列诊断率为55%,澳大利亚队列为42%。
  • 在7例患者中检出新型候选基因变异:DNAH12、DRC1、MDC1、PACRG、SSPL2C和TPTE2。
  • 1例患者携带四个候选基因的变异,无法确定哪个变异导致严重精子活力缺陷。

临床怎么用

  • 外显子组测序可作为严重精子活力障碍患者的病因诊断工具,有助于遗传咨询。

局限性

  • 由于缺乏父母DNA,未能评估新发或母源遗传的显性变异频率,也无法确定所有病例中突变是否位于两个等位基因上。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the causative genetic variants in patients with male infertility due to severe sperm motility disorders? SUMMARY ANSWER: We identified high confidence disease-causing variants in multiple genes previously associated with severe sperm motility disorders in 10 out of 21 patients (48%) and variants in novel candidate genes in seven additional patients (33%). WHAT IS KNOWN ALREADY: Severe sperm motility disorders are a form of male infertility characterised by immotile sperm often in combination with a spectrum of structural abnormalities of the sperm flagellum that do not affect viability. Currently, depending on the clinical sub-categorisation, up to 50% of causality in patients with severe sperm motility disorders can be explained by pathogenic variants in at least 22 genes. STUDY DESIGN, SIZE, DURATION: We performed exome sequencing in 21 patients with severe sperm motility disorders from two different clinics. PARTICIPANTS/MATERIALS, SETTING, METHOD: Two groups of infertile men, one from Argentina (n = 9) and one from Australia (n = 12), with clinically defined severe sperm motility disorders (motility <5%) and normal morphology values of 0-4%, were included. All patients in the Argentine cohort were diagnosed with DFS-MMAF, based on light and transmission electron microscopy. Sperm ultrastructural information was not available for the Australian cohort. Exome sequencing was performed in all 21 patients and variants with an allele frequency of <1% in the gnomAD population were prioritised and interpreted. MAIN RESULTS AND ROLE OF CHANCE: In 10 of 21 patients (48%), we identified pathogenic variants in known sperm assembly genes: CFAP43 (3 patients); CFAP44 (2 patients), CFAP58 (1 patient), QRICH2 (2 patients), DNAH1 (1 patient) and DNAH6 (1 patient). The diagnostic rate did not differ markedly between the Argentinian and the Australian cohort (55% and 42%, respectively). Furthermore, we identified patients with variants in the novel human candidate sperm motility genes: DNAH12, DRC1, MDC1, PACRG, SSPL2C and TPTE2. One patient presented with variants in four candidate genes and it remains unclear which variants were responsible for the severe sperm motility defect in this patient. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: In this study, we described patients with either a homozygous or two heterozygous candidate pathogenic variants in genes linked to sperm motility disorders. Due to unavailability of parental DNA, we have not assessed the frequency of de novo or maternally inherited dominant variants and could not determine the parental origin of the mutations to establish in all cases that the mutations are present on both alleles. WIDER IMPLICATIONS OF THE FINDINGS: Our results confirm the likely causal role of variants in six known genes for sperm motility and we demonstrate that exome sequencing is an effective method to diagnose patients with severe sperm motility disorders (10/21 diagnosed; 48%). Furthermore, our analysis revealed six novel candidate genes for severe sperm motility disorders. Genome-wide sequencing of additional patient cohorts and re-analysis of exome data of currently unsolved cases may reveal additional variants in these novel candidate genes. STUDY FUNDING/COMPETING INTEREST(S): This project was supported in part by funding from the Australian National Health and Medical Research Council (APP1120356) to M.K.O.B., J.A.V. and R.I.M.L., The Netherlands Organisation for Scientific Research (918-15-667) to J.A.V., the Royal Society and Wolfson Foundation (WM160091) to J.A.V., as well as an Investigator Award in Science from the Wellcome Trust (209451) to J.A.V. and Grants from the National Research Council of Argentina (PIP 0900 and 4584) and ANPCyT (PICT 9591) to H.E.C. and a UUKi Rutherford Fund Fellowship awarded to B.J.H.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Oud MS, Houston BJ, Volozonoka L, et al. Exome sequencing reveals variants in known and novel candidate genes for severe sperm motility disorders. Hum Reprod. 2021. PMID: 34089056. doi:10.1093/humrep/deab099

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。